Neutropenia after rituximab treatment: new insights on a late complication.
about
Monoclonal antibody therapy and renal transplantation: focus on adverse effectsLow-dose rituximab in the treatment of acquired haemophilia.Review article: autoimmune hepatitis -- current management and challenges.The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.New developments in the management of Waldenström macroglobulinemiaB-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentEffect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.Current and future therapeutic approach for Waldenström's macroglobulinemia.Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Late-onset neutropenia after rituximab in ANCA-associated vasculitis.Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation.Biologics in dermatology: adverse effects.Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia.Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation.Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.Treatment of paraneoplastic cerebellar degeneration.Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma.Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia.
P2860
Q26826880-EAD88812-DE59-435F-9763-15700289B6ADQ33413790-B12EF390-FF57-4E37-A303-6CB79D94D343Q34369116-D818A2F1-9200-409A-B397-FD8A829284EBQ34486116-C10D8CCF-6AA8-4401-A057-F7C43AE9EBDFQ34553880-5E629E30-D5CA-404B-98FA-F731B1F0AD44Q35680023-DF41CB6B-F96B-4C72-B303-07C3EDE16C27Q37686026-A85A6939-6D78-4271-84A5-48FBF95460FFQ38101526-C05B95E9-64E9-480C-B5BD-707584572E63Q38154934-E5FA34BB-B30A-488A-A298-8141F88656E6Q38206050-96404F74-887A-41AA-A693-4F4DA3AF77CAQ38206820-E906D254-D972-42AA-A27A-39496964CB02Q38271339-788B86A9-D023-4CA5-B723-E9D11C062D51Q38795404-3B2DECC3-7B00-4209-86DA-0BF98AB68051Q39944154-8EABCC41-213B-4C07-8D15-9AFC211F46C2Q40272339-4A7617B6-9328-450C-8BFF-306A68E73B1AQ41120913-8CA13F2D-205C-4580-9982-66759F9E9BE9Q42217116-D4F38820-219F-438C-9553-AD4AA4107BD9Q42408161-4E61FD68-9317-41DC-9D21-B724CA661F27Q44150295-B7447F57-A8FA-4F66-9B6B-6182C40D21F0Q44410712-31E25188-7511-48C6-AF81-1461642E01C8Q45159970-5B31A59F-2717-4676-A94B-B4A557F603F7Q46242353-66E4A33D-F6F0-4A2C-9D13-CD5371606A09Q47587300-A080F7DB-470D-4123-8A8B-121E928C4B86Q51119875-D3B9848D-5857-4D85-8D0B-5A57D1F4DECEQ52776107-1BDE0EE0-A9A5-4F23-B546-23C9979146E0
P2860
Neutropenia after rituximab treatment: new insights on a late complication.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neutropenia after rituximab treatment: new insights on a late complication.
@en
Neutropenia after rituximab treatment: new insights on a late complication.
@nl
type
label
Neutropenia after rituximab treatment: new insights on a late complication.
@en
Neutropenia after rituximab treatment: new insights on a late complication.
@nl
prefLabel
Neutropenia after rituximab treatment: new insights on a late complication.
@en
Neutropenia after rituximab treatment: new insights on a late complication.
@nl
P2093
P1476
Neutropenia after rituximab treatment: new insights on a late complication.
@en
P2093
Meir Lahav
Ofer Shpilberg
Ofir Wolach
P356
10.1097/MOH.0B013E32834DA987
P577
2012-01-01T00:00:00Z